Movano Health Provides Business Update and Reports Third Quarter 2022 Financial Results

About this update from Corvex, Inc.

[{"type":"text","content":"Conference call begins at 2:00 p.m. Pacific time today\nPLEASANTON, Calif., Nov. 14, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update.\n\n \n \n \n \n \n \n\n \nHighlights from the third quarter and recent weeks include the following:\nMovano Health continues to expect to test the wearability and functionality of its smart device in beta programs with multiple strategic partners beginning in Q4 2022. In addition to conducting a beta program with Stanford University's Applied Sports Science department, Movano Health named Novant Health, an integrated system of medical centers that reported over $7 billion in revenue in 2021, as its second beta partner. With more than 1,800 physicians providing care through close to six million annual patient visits at nearly 800 locations across North Carolina, South Carolina and Georgia, Novant Health is seeking novel technology, like Movano Health's solutions, that can provide doctors greater visibility into patients' day-to-day health metrics. The beta program will involve Novant Health's internal teams as they evaluate the technology for its possible use cases for patients and is expected to kick off in the near term.The Company is also preparing for two additional beta programs – one with a major global pharmaceutical company and the other with a leading patient-focused medical device company. Movano Health continues to believe that leading pharmaceutical and medical device enterprises are seeking to participate in the Company's beta programs as a result of Movano Health's commitment to deploying medical-grade data in a consumer wearable device, which has the potential to help these enterprises improve remote care, as well as provide critical clinical trial and post-market surveillance health data.Movano Health has its sights set on its first FDA submission for its heart rate and blood oxygen saturation (SpO2) data. Following a successful pilot hypoxia study in July 2022, which compared the accuracy of Movano Health's heart rate and SpO2 data to reference devices, Movano Health completed a pivotal hypoxia study in October 2022. During the pilot study, Movano Health's ...

More updates from Corvex, Inc.